查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1465179

進行性肌肉骨化症市場：按產品、給藥途徑和最終用戶 - 全球預測 2024-2030

Fibrodysplasia Ossificans Progressiva Market by Offering (Drug Type, Treatment), Route of Administration (Oral, Parenteral, Topical), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年進行性肌肉骨化症的市場規模為4.7046億美元，2024年達到4.9459億美元，2030年達到6.7565億美元，複合年成長率預計為5.30%。

進行性肌肉骨化症(FOP) 是一種嚴重且嚴重的遺傳性疾病，其特徵是肌肉、韌帶和結締組織等軟組織逐漸被骨骼取代（骨化）。在此過程中，骨骼外部形成骨骼，限制運動。該疾病是由ACVR1基因突變引起的，該基因突變會影響人體的修復機制，導致纖維組織在損傷或受傷後取代骨骼。進行性肌肉骨化症的全球發生率不斷增加，擴大了對進行進行性肌肉骨化症不良相關治療的需求。醫療保健專業人員和公眾意識的提高，以及政府機構對罕見疾病的資金和支持的增加，正在導致診斷和治療方法選擇的改善，支持市場成長。開發有效的 FOP治療方法的高昂研發成本以及核准治療罕見疾病的藥物的嚴格監管流程正在阻礙市場成長。基因研究和標靶治療方法的進步為進行進行性肌肉骨化症相關的突破性治療方法提供了潛力，正在為市場成長創造機會。

主要市場統計
基準年[2023] 47046萬美元
預測年份 [2024] 4.9459 億美元
預測年份 [2030] 67565萬美元
複合年成長率（%） 5.30%

越來越需要 parvarotene 來抑制所提供的 FOP 中異位性骨化症的進展

非類固醇消炎劑(NSAID) 通常用於控制 FOP 患者發作時的疼痛和腫脹。儘管這些藥物不能阻止疾病的進展，但它們可以透過減少不適來顯著改善患者的生活品質。雙磷酸鹽是一種抑制骨質流失的藥物。用於減緩 FOP 患者的骨骼變化。雙磷酸鹽在 FOP 中的有效性仍在調查中，並且正在進行研究以更好地了解其在疾病管理中的作用。皮質類固醇用於發作的早期階段，以減輕發炎和組織腫脹。皮質類固醇的使用對於急性治療至關重要，但由於可能存在長期副作用，因此通常只能短期使用。 Parovarotene 是一種維生素A酸受體 γ促效劑，可望抑制 FOP異位性骨化症的進展。 Parovarotene 是 FOP 治療的一個重要突破，為改善這種疾病的治療帶來了希望。藥物治療仍然是 FOP 治療的基石，可以解決症狀、控制疼痛，如果使用含有 parovarotene 的藥物，還可能減緩疾病進展。藥物治療的選擇需要仔細考慮個別患者的病情和疾病階段。職能治療在維持 FOP 患者的活動能力和生活品質方面發揮重要作用。職能治療師與患者合作，制定日常活動策略，盡量減少受影響區域的壓力，防止疾病發作並解決疾病引起的限制。由於誘發進一步骨化的風險，FOP 患者的手術需謹慎進行。通常僅當骨骼異常導致嚴重損傷或危及生命的問題並且無法保守治療時才使用手術。每個病例都需要仔細評估，以平衡手術的好處與惡化病情的可能性。

最終使用者：醫院中大量使用進行進行性肌肉骨化症藥物用於 FOP 的診斷、治療和持續管理

醫院是進行進行性肌肉骨化症(FOP) 的重要第一線最終使用者。這些設施是 FOP 診斷、治療和持續管理的主要中心。鑑於 FOP 的複雜性，醫院通常會協調多學科治療團隊，包括遺傳學、整形外科和內分泌學專家，以解決與 FOP 相關的各種進行性症狀。醫院在為行動不便或呼吸困難的 FOP 患者提供緊急治療方面也發揮著至關重要的作用。研究機構對於促進 FOP 的理解和治療至關重要。我們正在努力透過深入研究 FOP 的遺傳、分子和細胞背景來發現新的治療標靶和策略。這些實體是評估新治療方法有效性和安全性的臨床試驗的支柱。研究機構和製藥商之間的合作對於將創新治療方法從實驗室帶到臨床至關重要。此外，研究機構經常帶頭進行教育舉措，以傳播 FOP 意識並教育醫學界和公眾。專科診所在進行進行性肌肉骨化症治療生態系中發揮獨特的作用。這些診所通常由具有 FOP 專業知識的多學科團隊營運，根據 FOP 患者的複雜需求提供專門護理。從遺傳諮詢和物理治療到先進的疼痛管理和疾病進展監測，專科診所提供一系列護理，旨在提高生活品質並減少與 FOP 相關的併發症。我們也促進患者和家庭之間的社區，並提供治療以外的支持。

區域洞察

美洲 FOP 市場的特點是先進的醫療基礎設施和專注於罕見疾病治療的研發生態系統。還有多個意識計劃和患者支持組織支持研究經費和患者護理。 FDA 指定的孤兒藥等監管激勵措施加快了新治療方法的核准流程，並使美洲成為 FOP治療方法開發和商業化的重要地區。在亞太地區，人們對包括 FOP 在內的罕見疾病的認知不斷提高，診斷率不斷提高。由於中國、日本和澳洲等國家醫療保健系統的改善和醫療保健支出的增加，該市場正在逐漸發展。然而，挑戰依然存在，例如獲得治療的機會有限以及缺乏針對罕見疾病的專門醫療設施。歐洲、中東和非洲地區的 FOP 市場多元化，歐洲在臨床研究、藥物開發和患者支持活動方面處於領先地位。歐洲國家受益於強大的公共衛生保健系統和鼓勵罕見疾病研究的政策，包括對罕見疾病藥物開發的大量資金和獎勵。該市場由政府、研究機構和製藥公司之間的協作系統支援。同時，中東和非洲面臨更嚴峻的挑戰，包括認知低、研究少、獲得治療的機會有限。然而，持續努力改善醫療基礎設施和建立罕見疾病治療的國際合作是非洲市場未來的積極指標。

FPNV定位矩陣

FPNV 定位矩陣對於評估進行進行性肌肉骨化症市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對進行進行性肌肉骨化症市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.進行性肌肉骨化症市場的市場規模與預測為何？

2.在進行進行性肌肉骨化症市場預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.進行性肌肉骨化症市場的技術趨勢和法規結構是什麼？

4.進行性肌肉骨化症市場主要供應商的市場佔有率為何？

5.進入進行性肌肉骨化症市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 進行性肌肉骨化症的發生率增加
      • 提高醫療保健專業人員和公眾對罕見疾病和遺傳疾病的認知
    • 抑制因素
      • 進行進行性肌肉骨化症治療的開發成本很高
    • 機會
      • 增加研發活動以開發新治療方法
      • 政府對罕見疾病的資助和核准
    • 任務
      • 對進行性肌肉骨化症的認知較低
  • 市場區隔分析
    • 提供詳細資訊：對 parvarotene 的需求不斷增加，其抑制 FOP異位性骨化症的進展
    • 最終使用者：進行性肌肉骨化症藥物經常在醫院用於 FOP 的診斷、治療和持續管理。
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章進行性肌肉骨化症市場：透過提供

  • 藥物類型
  • 過程

第7章進行性肌肉骨化症市場：依給藥途徑

  • 口服
  • 胃腸外的
  • 話題

第 8 章進行性肌肉骨化症市場：依最終用戶

  • 醫院
  • 調查機構
  • 專科診所

第9章北美和南美的進行性肌肉骨化症市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區進行性肌肉骨化症市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的進行性肌肉骨化症市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • FDA核准Ibsen 的進行性肌肉骨化症治療
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-9E71DF483BA8

[181 Pages Report] The Fibrodysplasia Ossificans Progressiva Market size was estimated at USD 470.46 million in 2023 and expected to reach USD 494.59 million in 2024, at a CAGR 5.30% to reach USD 675.65 million by 2030.

Fibrodysplasia ossificans progressiva (FOP) is a rare, severe genetic disorder characterized by the gradual replacement of soft tissue, such as muscles, ligaments, and connective tissue, by bone (ossification). This process leads to bone-forming outside the skeleton, restricting movement. The disorder is caused by a mutation in the ACVR1 gene, which impacts the body's repair mechanism, causing fibrous tissues to be replaced by bone after damage or injury. Rising fibrodysplasia ossificans progressiva incidence rates worldwide are expanding the need for treatments associated with fibrodysplasia ossificans progressiva. The elevating awareness among healthcare professionals and the public, with increased funding and support from government bodies for rare diseases, is improving diagnostics and the availability of treatment options, subsequently supporting market growth. High R&D costs for developing effective treatments for FOP and stringent regulatory processes for approving drugs for rare diseases are hampering the market's growth. Increasing progress in genetic research and targeted therapy approaches that offer potential breakthrough treatments associated with fibrodysplasia ossificans progressiva creates opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 470.46 million
Estimated Year [2024] USD 494.59 million
Forecast Year [2030] USD 675.65 million
CAGR (%) 5.30%

Offering: Rising need for palovarotene for reducing the progression of heterotopic ossification in FOP

Nonsteroidal anti-inflammatory drugs (NSAIDs) are often specified to manage pain and swelling associated with flare-ups in FOP patients. While these medications do not halt the progression of the disease, they can vastly improve the quality of life for affected individuals by reducing discomfort. Bisphosphonates are a class of medications that prevent the loss of bone mass. They are used to slow down the skeletal changes in FOP patients. The effectiveness of bisphosphonates in FOP is still under investigation, with research ongoing to better understand their role in managing the condition. Corticosteroids are used during the early stages of flare-ups to reduce inflammation and tissue swelling. Their use is typically short-term due to potential long-term side effects but can be crucial in managing acute phases of the condition. Palovarotene is a retinoic acid receptor gamma agonist that has shown promise in reducing the progression of heterotopic ossification in FOP. It represents a significant breakthrough in treating FOP, offering hope for improved management of this condition. Medication remains a cornerstone of FOP management, addressing symptoms, managing pain, and, in the case of drugs including, palovarotene, potentially slowing disease progression. The choice of medication requires careful consideration of the individual's condition and the phase of the disease. Occupational therapy plays a vital role in maintaining mobility and quality of life for individuals with FOP. Therapists work with patients to develop strategies for performing daily activities with minimal stress on affected areas, thus preventing flare-ups and managing the limitations imposed by the disease. Surgery in FOP patients is approached with great caution due to the risk of triggering further ossification. It is generally reserved for cases where skeletal abnormalities cause severe functional impairments or life-threatening problems that cannot be managed conservatively. Each case requires careful evaluation to balance the benefits of surgery against the potential for exacerbating the condition.

End-User: High usage of fibrodysplasia ossificans progressiva drugs in hospitals for diagnosis, treatment, and ongoing management of FOP

Hospitals represent a critical front-line end-user group in fibrodysplasia ossificans progressiva (FOP). These institutions serve as primary centers for diagnosis, treatment, and ongoing management of FOP. Given the complexity of FOP, hospitals often coordinate multidisciplinary care teams, encompassing specialists in genetics, orthopedics, and endocrinology, to address the diverse and progressive symptomology associated with the disease. Hospitals also play a pivotal role in providing emergency care for FOP patients who may suffer from flare-ups leading to immobility or respiratory issues. Research Institutes are integral to advancing our understanding and treatment of fibrodysplasia ossificans progressiva. They dive deep into FOP's genetic, molecular, and cellular underpinnings, striving to uncover novel therapeutic targets and strategies. These entities are the backbone of clinical trials assessing the efficacy and safety of novel treatments. Collaborations among research institutes and pharmaceutical manufacturers are vital for bringing innovative therapies from the bench to the bedside. Moreover, research institutes often spearhead educational initiatives to extend awareness and educate the medical community and public about FOP. Specialty Clinics play a unique role in the care ecosystem for fibrodysplasia ossificans progressiva. Often staffed by multidisciplinary teams with specific expertise in FOP, these clinics offer specialized care tailored to the complex needs of FOP patients. From genetic counseling and physiotherapy to advanced pain management and surveillance for disease progression, specialty clinics provide a continuum of care designed to improve quality of life and mitigate the complications associated with FOP. They also foster a community among patients and families, offering support beyond medical treatment.

Regional Insights

The market for fibrodysplasia ossificans progressiva (FOP) in the Americas is characterized by a robust research and development ecosystem, benefiting from advanced healthcare infrastructure and a strong emphasis on rare disease treatment. There are also multiple awareness programs and patient advocacy groups that support research funding and patient care. Regulatory incentives such as orphan drug designation by the FDA expedite the approval process for new treatments, making the Americas a critical region for FOP therapeutic development and commercialization. Asia-Pacific is witnessing a growing awareness and increasing diagnosis rates of rare diseases, including FOP. This market is gradually evolving with improved healthcare systems and increased healthcare spending in countries including China, Japan, and Australia. However, challenges such as limited access to treatment and a lack of specialized healthcare facilities for rare diseases prevail. The EMEA region's FOP market is diverse, with Europe leading in clinical research, drug development, and patient advocacy. European countries benefit from strong public healthcare systems and policies encouraging rare disease research, including substantial funding and incentives for orphan drug development. Collaborations between governments, research institutions, and pharmaceutical companies support the market. In contrast, the Middle East and Africa face more profound challenges, including lower awareness, scant research, and limited treatment access. However, ongoing efforts to establish better healthcare infrastructure and international collaborations for rare disease treatment are positive indicators for the market's future in African regions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Fibrodysplasia Ossificans Progressiva Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Fibrodysplasia Ossificans Progressiva Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Fibrodysplasia Ossificans Progressiva Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Accord Healthcare, Inc, Amgen Inc., BioCryst Pharmaceuticals, Inc., bioMerieux S.A., Blueprint Medicines Corporation, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Incyte Corporation, Ipsen Pharma, Merck & Co Inc., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Fibrodysplasia Ossificans Progressiva Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Offering
    • Drug Type
      • Anti-inflammatory Medications
      • Bisphosphonates
      • Corticosteroids
      • Palovarotene
    • Treatment
      • Medication
      • Occupational Therapy
      • Surgery
  • Route of Administration
    • Oral
    • Parenteral
    • Topical
  • End-User
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Fibrodysplasia Ossificans Progressiva Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Fibrodysplasia Ossificans Progressiva Market?

3. What are the technology trends and regulatory frameworks in the Fibrodysplasia Ossificans Progressiva Market?

4. What is the market share of the leading vendors in the Fibrodysplasia Ossificans Progressiva Market?

5. Which modes and strategic moves are suitable for entering the Fibrodysplasia Ossificans Progressiva Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of fibrodysplasia ossificans progressiva diseases
      • 5.1.1.2. Rising awareness among healthcare professionals and the public for rare and genetic diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development of fibrodysplasia ossificans progressiva treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising research & development activities to develop novel fibrodysplasia ossificans progressiva treatments
      • 5.1.3.2. Availability of government funding and approvals for rare diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness for the fibrodysplasia ossificans progressiva
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Rising need for palovarotene for reducing the progression of heterotopic ossification in FOP
    • 5.2.2. End-User: High usage of fibrodysplasia ossificans progressiva drugs in hospitals for diagnosis, treatment, and ongoing management of FOP
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Fibrodysplasia Ossificans Progressiva Market, by Offering

  • 6.1. Introduction
  • 6.2. Drug Type
  • 6.3. Treatment

7. Fibrodysplasia Ossificans Progressiva Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral
  • 7.4. Topical

8. Fibrodysplasia Ossificans Progressiva Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Research Institutes
  • 8.4. Specialty Clinics

9. Americas Fibrodysplasia Ossificans Progressiva Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Fibrodysplasia Ossificans Progressiva Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Fibrodysplasia Ossificans Progressiva Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Approves Ipsen Fibrodysplasia Ossificans Progressiva Treatment
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET RESEARCH PROCESS
  • FIGURE 2. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET DYNAMICS
  • FIGURE 7. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PALOVAROTENE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PALOVAROTENE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY MEDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY MEDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 144. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 154. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 164. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 174. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 184. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 194. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 204. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 214. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 224. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 234. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 255. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 256. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 266. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 276. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 286. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE FI